Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) for GEMTESA® (vibegron), proposed for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults, and OAB with symptoms of urge urinary incontinence, urgency, urinary frequency, and nocturia in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH), has been accepted for review by Health Canada.
asserted
Submission → announce → Canada
“For patients living with overactive bladder, and for adult males managing OAB alongside BPH, having access to an effective treatment option can make a real difference in daily life,” said Samira Sakhia, President and Chief Executive Officer, Knight Therapeutics Inc.
asserted
Sakhia → live → life
“The acceptance of our submission for GEMTESA® in Canada is an important step toward bringing this therapy to the patients who need it.
asserted
who → bring → it
At Knight, our commitment goes beyond building our portfolio.
asserted
commitment → go → portfolio
We are dedicated to improving access to innovative therapies that improve patient outcomes.
asserted
that → dedicate → outcomes
We are also pleased to advance this milestone together with our partner, Sumitomo Pharma America Inc.”
asserted
We → please → partner
In June 2025, Knight entered into exclusive supply and distribution agreements with Sumitomo’s Pharma America (SMPA) to commercialize GEMTESA®, as well as ORGOVYX® (relugolix) and MYFEMBREE® (relugolix/estradiol/norethindrone acetate) in Canada.
asserted
Knight → enter → Canada
About GEMTESA®
GEMTESA® (vibegron) is marketed in the US for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults and in adult males taking medication for benign prostatic hyperplasia (BPH).
asserted
GEMTESA → market → hyperplasia
GEMTESA® works by selectively targeting β3 adrenergic receptors to reduce OAB symptoms through the relaxation of the bladder detrusor muscle to increase capacity.1
GEMTESA® is a registered trademark of Sumitomo Pharma Co., Ltd.
asserted
GEMTESA → work → Co.
About Overactive Bladder
Overactive Bladder (OAB) is a symptom syndrome characterized by urinary urgency, usually accompanied by increased urinary frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection (UTI) or other obvious pathology.2,3
asserted
Bladder → characterize → infection
These symptoms are commonly associated with involuntary contractions of the detrusor muscle, although they can also result from other forms of lower urinary tract dysfunction.2
asserted
they → associate → dysfunction.2
The pooled global prevalence of OAB was estimated at approximately 20%, with prevalence higher in women (nearly 22%) than in men (roughly 16%).4
asserted
prevalence → estimate → men
Canadian population based estimates reported in the Canadian Urological Association (CUA) guideline from May 2017 indicate an overall prevalence of approximately 14 to 18%, with prevalence increasing with age.5
About
uncertain
prevalence → base → age.5
Benign Prostatic Hyperplasia (BPH) is a histologic diagnosis describing the proliferation of smooth muscle and epithelial cells within the prostatic transition zone, which commonly leads to enlargement of the prostate gland.6
asserted
which → describe → gland.6
In men presenting with lower urinary tract symptoms (LUTS), the symptoms are frequently presumed to arise from bladder outlet obstruction caused by the enlarged prostate.6 Even when the bladder outflow obstruction is relieved surgically, storage symptoms consistent with overactive bladder (OAB) may persist; detrusor overactivity has been reported in approximately 20% to 40% of men.7
uncertain
overactivity → present → %
LUTS are conventionally divided into storage, voiding, and postmicturition symptoms.2
asserted
LUTS → divide → storage
In the population-based EPIC study, storage symptoms were the most prevalent category among men (51.3%), exceeding both voiding (25.7%) and postmicturition (16.9%) symptoms.8
BPH becomes increasingly prevalent with age, and symptoms of OAB, which are often associated with BPH, are frequently misattributed to normal aging.
asserted
which → base → aging
In the United States, approximately 14 million men are living with BPH, and up to 75% of these individuals experience OAB symptoms.9,10
asserted
% → live → individuals
Despite this high prevalence, OAB symptoms in men often remain unrecognized, particularly in those with underlying BPH.
asserted
symptoms → remain → BPH
It is estimated that up to 80% of OAB cases in men may go undiagnosed.11,12
About The COURAGE Trial
The COURAGE trial (NCT03902080; URO-901-3005) was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating GEMTESA® 75 mg once daily versus placebo over 24 weeks in men ≥45 years of age with symptoms of overactive bladder (OAB) who were receiving pharmacological therapy with α-blockers, with or without 5α-reductase inhibitors, for BPH.
uncertain
who → estimate → BPH
Of 1,105 participants randomized 1:1 to vibegron or placebo, 965 (87.3%) completed the trial.
asserted
965 → randomize → trial
The study met both co-primary endpoints at Week 12, demonstrating statistically significant reductions from baseline versus placebo in mean daily micturitions (least squares mean difference −0.74; 95% CI −1.02, −0.46; P < .0001) and urgency episodes (−0.95; 95% CI −1.37, −0.54; P < .0001).
asserted
P → meet → micturitions
GEMTESA® also met all prespecified secondary endpoints, with significant reductions versus placebo in nocturia episodes and urge urinary incontinence (UUI) episodes.
asserted
® → meet → episodes
Adverse events occurring in ≥ 2% of participants were hypertension, COVID-19, UTI, and hematuria.13
About
asserted
events → occur → participants
EMPOWUR was a 12-week, double-blind, placebo-controlled Phase 3 study evaluating vibegron 75 mg versus placebo in adults with OAB, as part of an extensive development program involving more than 4,000 OAB patients.
asserted
EMPOWUR → control → patients
The study demonstrated that treatment with GEMTESA® resulted in statistically significant reductions in daily urge urinary incontinence episodes, micturition episodes, and urgency episodes, as well as an increase in volume voided, compared to placebo.
asserted
treatment → demonstrate → placebo
A long-term extension of the EMPOWUR study was also conducted under double-blind conditions.
asserted
extension → conduct → conditions
The most common adverse reactions reported in 2% or more of patients treated with GEMTESA® were headache, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.1,14
About
asserted
reactions → report → GEMTESA
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America.
asserted
Inc. → headquarter → Canada
Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM.
asserted
subsidiaries → operate → Medical
Knight Therapeutics Inc.‘s shares trade on the TSX under the symbol GUD.
asserted
shares → trade → GUD
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries.
asserted
document → contain → Inc.
These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.
uncertain
results → look → statements
Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect.
uncertain
many → consider → Inc.
Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.‘s Annual Report and in Knight Therapeutics Inc.‘s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca.
uncertain
results → cause → www.sedarplus.ca
Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.
asserted
Inc. → disclaim → law
This press release was published by a CLEAR® Verified individual.
asserted
release → publish → individual
The Aporia
